2018 American Transplant Congress
Treatment Outcomes of Recurrent Primary Focal Segmental Glomerulosclerosis (FSGS) after Kidney Transplantation
Introduction: Primary FSGS can recur in the renal allograft and is associated with poor graft outcomes. There is no established therapeutic intervention to prevent or…2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…2018 American Transplant Congress
Redo Kidney Transplant in FSGS
Kidney and Pancreas Transplant Program, MedStar Georgetown Transplant Institute, Washington, DC.
Objective: Analyze risk of graft failure due to recurrent FSGS in patients with prior failed kidney transplants under consideration for a subsequent transplant.Results: We identified…2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…2018 American Transplant Congress
Thirty-Six Consecutive Kidney Transplants in Recipients with Atypical Hemolytic Uremic Syndrome: A Single-Centre Experience
Background. Due to high recurrence rate, poor kidney transplant (KTx) survival has been reported for recipients with atypical hemolytic uremic syndrome (aHUS). More recently, prophylaxis…2018 American Transplant Congress
Impact of Antecedent Malignancy on Kidney Transplant Outcomes: Patient, Graft, and Cancer-Free Survival
OBJECTIVE: Non-skin pretransplant malignancy (NSPTM) has historically been considered a relative contraindication to kidney transplantation (KT). In addition to the conventional risk factors for cancer,…2018 American Transplant Congress
HLA-DR4 Matching and Hepatocellular Carcinoma Recurrence after Liver Transplantation
PURPOSE: The phenomenon of graft versus host disease after orthotopic liver transplantation (OLT) is estimated at approximately 1-2%, suggesting that under some circumstances, the graft…2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…2017 American Transplant Congress
Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays.
Background & aims: Untreated atypical haemolytic syndrome (aHUS) leads to ESRD and may recur after renal transplantation. Eculizumab (Ecu), a humanized antibody inhibiting terminal C5…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 15
- Next Page »